propanc biopharma, inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in australia. its lead product is prp, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. the company has a research collaboration with university of jaã©n to commence the pop1 joint drug discovery program. the company was formerly known as propanc health group corporation and changed its name to propanc biopharma, inc. in april 2017. propanc biopharma, inc. was founded in 2007 and is based in camberwell, australia.
Company profile
Ticker
PPCB
Exchange
Website
CEO
James Nathanielsz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Propanc Health Group Corp
SEC CIK
Corporate docs
Subsidiaries
Propanc Pty Ltd • Propanc (UK) Ltd ...
IRS number
300662986
PPCB stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
11 Mar 24
10-Q
2024 Q2
Quarterly report
20 Feb 24
NT 10-Q
Notice of late quarterly filing
14 Feb 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Dec 23
10-Q
2024 Q1
Quarterly report
14 Nov 23
D
$40.00 k in debt / options / securities to be acquired, sold $40.00 k, 1 investor
3 Nov 23
8-K
Other Events
30 Oct 23
8-K
Entry into a Material Definitive Agreement
26 Oct 23
D
$61.00 k in debt / options / securities to be acquired, sold $61.00 k, 1 investor
26 Oct 23
Latest ownership filings
4
JOSEF ZELINGER
23 Aug 23
SC 13G
Sylva International LLC
8 Sep 21
4
Julian Norman Kenyon
20 Aug 21
4
James Andrew Nathanielsz
20 Aug 21
3
JOSEF ZELINGER
20 Aug 21
SC 13G
Oasis Capital, LLC
7 Jul 20
SC 13G
L2 Capital, LLC
7 Jul 20
3
Carlo M Campiciano
28 Jun 19
4
Julian Norman Kenyon
22 May 19
4
James Andrew Nathanielsz
17 May 19
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2021
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.00 k |
Total shares | 20.01 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LVM Capital Management | 20.01 k | $5.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jul 23 | Josef Zelinger | Common Stock Purchase Warrant Common Stock | Grant | Acquire A | Yes | No | 0.01 | 15,000,000 | 150.00 k | 15,000,000 |